Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Allergan Shares Jump on Pfizer Deal Speculation

By Pharmaceutical Processing | October 29, 2015

Shares of Allergan jumped 15 percent in premarket trading Thursday on reports that a deal may be in the works with Pfizer Inc., which would be just the latest in a string of massive pharmaceutical mergers.

A deal between the pharmaceutical companies, as reported by the Wall Street Journal, would create a massive drug development company with treatments for a wide range of conditions ranging from high cholesterol to erectile dysfunction.

Citi analyst Liav Abraham pointed out that Pfizer executives have talked openly about a corporate inversion, a maneuver in which a U.S. company reincorporates in another country by acquiring another company there to take advantage of lower tax rates.

Allergan, based in Dublin, would be among Pfizer’s most likely targets, Abraham said.

Inversions have become a hot political topic, raising the ire of lawmakers in Washington, and the subject came up in Wednesday’s Republican presidential debate.

Last week, billionaire Carl Icahn said that he was setting up a $150 million super PAC bent on revising U.S. corporate tax law and ending the practice of inversions.

Allergan PLC is best known for its wrinkle treatment Botox. In March, Ireland-based Actavis closed its $66 billion buyout of the company and changed its corporate name to Allergan. In July, the company agreed to sell its generic business to Teva Pharmaceutical Industries Ltd. for about $40 billion.

Allergan stock rose $42.80 to $330.01 before the start of regular trading.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE